Altimmune Inc Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers Conference Call Transcript
Greetings. Welcome to Altimmune, Inc. ALT-801 interim data call. (Operator Instructions) Please note, this conference is being recorded.
At this time, I'll now hand the call over to Stacey Jurchison. Please go ahead, Stacey.
Thank you, Rob, and good morning, everyone. Thank you for joining us. Members of the Altimmune team participating on the call today are Vipin Garg, Chief Executive Officer; Scott Harris, Chief Medical Officer; Scot Roberts, Chief Scientific Officer; and Will Brown, Chief Financial Officer.
Please note that we issued a press release this morning, which is the subject of our discussion today. You may find a copy of this press release on the IR section of our website.
Before we begin, I'd like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for purpose of safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
Altimmune
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |